To The Moon

Executive Summary

$UnitedHealth(UNH)$ reports Q4 2025 and full-year results Monday, January 27, before the bell. Consensus calls for $2.09 per share on $113.64 billion in revenue. That's a 69.3% earnings collapse from Q4 2024. Our proprietary Entry Indicator sits at -1.00, the most bearish signal possible, flagging structural breakdown. The options market prices in a 4.77% earnings move. That's your corridor: $369.86 to $335.85. The stock sits at $356.26, a full $16.26 above Max Pain at $340. Dealers are pulling the stock toward that level. This is a profitability crisis, not a revenue story.

The Earnings Risk Corridor: 4.77% Expected Move

The market expects UNH to swing $16.99 in either direction post-earnings. Upper bound at $369.86. Lower bound at $335.85. The 4.77% implied move is modest given the magnitude of the crisis UnitedHealth is navigating. This company missed earnings in Q1 2025 for the first time since the 2008 financial crisis. It suspended guidance in May. It withdrew guidance entirely before reinstating conservative targets in July.

Compare this to UnitedHealth's recent track record. The company beat estimates in only two of the last four quarters. The average earnings surprise sits at negative 2.3%. Q3 saw adjusted EPS of $2.92 versus $2.81 expected, but that "beat" masked a disaster underneath. The Medical Care Ratio (MCR) hit 89.9%, up 470 basis points year-over-year. Operating margin collapsed to 2.1% from 5.6%. Optum Health earnings fell 88% to a 1% operating margin. This is not a company demonstrating control.

Microstructure & Max Pain Analysis

Current price of $356.26 trades $16.26 above Max Pain at $340. The Put/Call ratio of 0.89 shows slightly more puts than calls, consistent with defensive positioning. This creates strong pin risk. Dealers profit when options expire worthless. With expiration in 6 days and the stock extended above Max Pain, there's gravitational pull toward $340. If UNH trades sideways or drifts lower into Friday, theta decay accelerates, and option sellers win.

The technical setup supports this magnet effect. UNH collapsed nearly 50% from over $600 per share in early 2025 to $310 in the summer. The stock has recovered to $356, but remains 40% below its 2024 highs. The rally off the lows reflects hope that CEO Stephen Hemsley can fix the MCR crisis. But hope is not a strategy. The stock is vulnerable to any disappointment on 2026 guidance. Mean reversion favours a drift back toward $340, killing both call and put premiums.

Analyst Consensus vs. Proprietary Signal: The Disconnect

Wall Street is cautious but not bearish enough. The consensus rating is "Hold" with a Zacks Rank #3. Analysts expect $2.09 EPS for Q4, a 69.3% drop from the prior year. Full-year 2025 consensus sits at $16.30, down 41.1% from 2024. This is the worst annual earnings decline in company history outside of financial crises. The Street expects 2026 to mark stabilization, not recovery. Management has set expectations low. The goal is to stop the bleeding, not to grow.

Our Entry Indicator tells a harsher story. At -1.00, the signal sits at the maximum bearish threshold. This suggests the MCR crisis is not priced in, even after the 50% drawdown. Revenue growth of 12.7% masks the profitability collapse. Investors are watching the wrong metric. UnitedHealth's problem is not top-line growth. The problem is that the company is paying out $90 in medical claims for every $100 in premiums collected, leaving almost nothing for operating costs and profit.

Three factors drive this bearish signal. First, the MCR crisis shows no signs of structural improvement. Management guided Q4 MCR to 89-89.5%. Wall Street expects 92.2%, implying costs are running even hotter than the company forecasted. Second, Optum Health is no longer the growth engine. Operating margins collapsed from 8.3% to 1% in Q3. The high-margin business that insulated UnitedHealth from insurance volatility has failed. Third, the aggressive repricing strategy for 2026 carries execution risk. UnitedHealth is raising rates and cutting unprofitable members. If this forces healthy members to leave and keeps sick members, the plan backfires. The company could end up with a sicker, more expensive member base requiring even higher rates. That's a death spiral.

Key Catalysts: What's Driving the Stock Right Now

MCR Explosion: The Medical Care Ratio spiked from around 82% in 2022 to 88% in 2025. Some quarters hit 89.9%. That's a 600 to 800 basis point increase. Each single basis point movement in MCR translates to over $34 million in pre-tax earnings impact. The difference between stabilization at 88% and deterioration to 90.5% is over $400 per share in valuation. UnitedHealth severely underestimated Medicare Advantage cost trends when it priced 2025 plans in mid-2024. Members are using more services than expected. Inpatient care accelerated through Q2 and Q3. ER visits, observation stays, and bundled services per visit all increased. Management admits it "significantly underestimated the accelerating medical trend" and "did not modify benefits or plan offerings sufficiently."

Stephen Hemsley Return: Former CEO Stephen Hemsley returned to the CEO role in May 2025 after Andrew Witty stepped down for personal reasons. Hemsley, 72, built UnitedHealth into the conglomerate it is today. He served as CEO from 2006 to 2017. His return signals the board believes this is a fix-it-yourself crisis, not a fundamental business model failure. Hemsley immediately bought over $25 million in UNH stock, a strong signal of management conviction. He was awarded a $60 million equity package tied to performance. His mandate is clear: restore profitability through disciplined pricing and operational rigor.

Berkshire Hathaway Investment: Warren Buffett's Berkshire Hathaway purchased roughly 5 million shares in Q2 2025, a $1.57 billion bet. This suggests long-term value investors see opportunity emerging despite the crisis. Buffett typically buys businesses with durable competitive advantages trading at depressed valuations. His investment indicates he believes the MCR spike is temporary, not structural. But Buffett has been wrong before. His investment does not guarantee a turnaround.

Aggressive Repricing Strategy: UnitedHealth launched aggressive repricing across the majority of its Medicare Advantage, individual, and commercial risk-based plans. The company is pricing 2026 Medicare Advantage plans at a conservative 10% medical cost trend, up from 7.5% in 2025. It expects to lose about 1 million members as it exits unprofitable segments. Management is prioritizing margins over growth. The company plans to enact targeted service area reductions in ACA markets, expecting a two-thirds reduction in enrollment. This will improve margins but destroy revenue growth in the near term.

Medicare Funding Cuts & Part D IRA Impacts: The MCR increase of 470 basis points in Q3 was driven by elevated cost trends, Medicare funding reductions from the Biden administration, and changes to the Part D program from the Inflation Reduction Act. These are structural headwinds that pricing alone cannot fix. Medicare rates are set by the government. UnitedHealth cannot simply charge more. It must manage costs or exit markets.

Optum Health Collapse: Optum Health's Q3 2025 earnings fell 88% to $255 million, an operating margin of 1%. This compares to $2.2 billion in operating earnings and an 8.3% margin in Q3 2024. Optum was supposed to be the stable, high-margin segment that offset insurance volatility. Instead, it collapsed. Medicare funding cuts, value-based care pressures, and heavy investment costs crushed profitability. This destroys the UnitedHealth investment thesis. Vertical integration only works if the care delivery arm generates strong margins.

Reputational Crisis: UnitedHealthcare CEO Brian Thompson was shot and killed on a Manhattan street on December 4, 2024, in a targeted attack. The suspect, Luigi Mangione, has been charged with murder and faces both state and federal charges. The killing sparked national outrage over health insurance industry practices, with widespread contempt and mockery toward Thompson and UnitedHealth on social media. A U.S. Senate committee concluded UnitedHealth used "aggressive tactics" to boost Medicare Advantage payments. The company faces a shareholder lawsuit alleging it misled investors by not adjusting its 2025 outlook after Thompson's death. UnitedHealth revised its outlook on April 17, 2025, causing the stock to drop 22% that day. The reputational damage is real and ongoing.

Change Healthcare Ransomware Attack: A massive February 2024 ransomware attack on Change Healthcare affected 190 million Americans. UnitedHealth was forced to provide over $9 billion in temporary funding to keep the system operational. The attack disrupted claims processing across the industry. Reports of a Justice Department probe into Medicare Advantage billing practices added further uncertainty. The combination of operational disruption, regulatory scrutiny, and reputational damage created a perfect storm.

The Trading Scenario: How to Play the Corridor

Bullish Case (Break Above $369.86): If UnitedHealth confirms that Q4 MCR came in below 90% and provides 2026 guidance showing stabilization at 88%, the stock could break the upper bound. Management needs to demonstrate that aggressive repricing is working without destroying the member base. Watch for any positive update on Optum margins returning to mid-single digits. If UnitedHealth beats on both revenue and margins while providing confident 2026 guidance, the stock targets $385. The Entry Indicator at -1.00 makes this outcome unlikely. Hemsley's credibility and Berkshire's vote of confidence provide support, but the fundamentals do not.

Bearish Case (Break Below $335.85): If UnitedHealth reports Q4 MCR above 92% or provides 2026 guidance that fails to show meaningful margin improvement, the lower bound breaks. The Entry Indicator at -1.00 flags severe vulnerability. Any signal that the repricing strategy is not working, that member attrition is higher than expected, or that Optum margins remain at 1% sends the stock to $320. The Brian Thompson reputational overhang remains. Any further regulatory scrutiny or negative publicity breaks support. The 777X-style overhang of ongoing legal proceedings creates uncertainty. The stock could retest summer lows at $310 if the turnaround narrative collapses.

Base Case (Pin to $340 Max Pain): Most likely outcome. UnitedHealth meets low expectations with Q4 MCR of 90-92%, confirms full-year EPS at $16.30, and provides cautious 2026 guidance calling for stabilization, not growth. Management tells investors to expect margins to stabilize in 2026 and return to growth in 2027. Stock drifts to $340 by Friday's expiration. Option sellers collect premium. Volatility collapses post-earnings. The Put/Call ratio of 0.89 and the narrow implied move (4.77%) support this view. UnitedHealth is in a holding pattern. The turnaround will take years, not quarters.

The Verdict

UnitedHealth sits at a crossroads. The MCR crisis destroyed the investment thesis. Margins collapsed. Optum failed. The stock fell 50%. Hemsley returned to fix it. Berkshire bought in. The company is repricing aggressively. But the Entry Indicator at -1.00 warns against chasing the rally off the lows. Max Pain at $340 creates a natural magnet. The 4.77% earnings move prices in execution risk on the repricing strategy, MCR stabilization, and Optum recovery. Watch the conference call at 8:00 AM ET for 2026 guidance. That's the binary catalyst. If management confirms MCR stabilization at 88% and provides a credible path to margin recovery, the stock holds $350. If they hedge, admit costs are still running hot, or signal further member losses, it breaks to $335 or lower. The bar is set extremely low. UnitedHealth just needs to not disappoint. Even that is uncertain.

For real-time earnings plays, proprietary signals, and live volatility tracking, visit optionsmovement.com.

Disclaimer: This content is for informational purposes only and does not constitute financial advice, investment advice, trading advice, or any other sort of advice. You should not treat any of the content as such. OptionsMovement.com does not recommend that any securities should be bought, sold, or held by you. Do your own due diligence and consult a licensed financial advisor before making any investment decisions.